Current approach to fracture prevention in postmenopausal osteoporosis

Clinical and Experimental Obstetrics and Gynecology

Volumn 31, Issue 4, 2004, Pages 251-255

  Kaplan, B ^a   Hirsch, M ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; PARATHYROID HORMONE; RALOXIFENE; STRONTIUM RANELATE; TIBOLONE; VITAMIN D;

BONE DENSITY; CLINICAL TRIAL; EXERCISE; FALLING; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; SENESCENCE;

BONE DENSITY; CALCIUM; COMPLEMENTARY THERAPIES; DIET; EXERCISE; FEMALE; FRACTURES, BONE; HUMANS; MASS SCREENING; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D;

EID: 12344272698     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Bowersox J., Wortman J.: "NIH Consensus Panel Addresses Osteoporosis Prevention". Diagnosis and Therapy, 2000, 17 (1).
2. Finkelstein J.S.: "Osteoporosis". Cecil Textbook of Medicine, 1999, 258.
3. Riggs B.L., Melton L.J.: "Involutional Osteoporosis". N. Engl. J. Med., 1986, 314, 1676.
4. Lindsay R., Silverman S.L., Cooper C., Hanley D.A., Barton I., Broy S.B. et al.: "Risk of new vertebral fracture in the year following a fracture". JAMA, 2001, 285, 320.
5. NIH Consence Statement, 1994, 12, 1.
6. Dawson-Hughes B., Dallai G.E., Krall E.A., Sadowski L., Sahyoun N., Tannenbaum S.: "A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women". N. Engl. J. Med., 1990, 323, 878.
7. Reid I.R., Ames R.W., Evans M.C. et al.: "Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trail". Am. J. Med., 1995, 98, 331.
8. Chevalley T., Rizzoli R., Nydegger V. et al.: "Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin D depleted elderly patients". Osteoporosis Int., 1994, 4, 245.
9. Recker R., Hinders S., Davies K.M. et al.: "Correcting calcium nutritional deficiency prevents spine fractures in elderly women". J. Bone Miner. Res., 1996, 11, 1961.
10. Larsen E.R., Mosekilde L., Foldspang A.J.: "Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study". J. Bone Miner. Res., 2004, 19, 370.
11. Dalsky G.P., Stocke K.S., Ehsani A.A., Slatopolsky E., Lee W.C., Birge S.J. Jr.: "Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women". Ann. Intern. Med., 1988, 108, 824.
12. Welsh L., Rutherford O.M.: "Hip bone mineral density is improved by high-impact aerobic exercise in postmenopausal women and men over 50 years". Eur. J. Appl. Physiol. Occup. Physiol., 1996, 74, 511.
13. Gutin B., Kasper M.J.: "Can vigorous Exercise play a role in osteoporosis prevention? A review". Osteopors. Int., 1992, 2, 55.
14. Fiatarone M.A., Marks B.C., Ryan N.D., Meredith C.N., Lipsitz L.A., Evans W.J.: "High intensity strength training in nonagenarians: Effects on skeletal muscle". JAMA, 1990, 263, 3029.
15. NIH Consensus Development Panel on Osteoporosis Prevention, diagnosis and therapy. JAMA, 2001, 285, 785.
16. Lindsay R., Gallagher J.C., Kleerekoper M., Pickar J.H.: "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women". JAMA, 2002, 287, 2668.
17. Recker R.R., Davies K.M., Dowd R.M., Heaney R.P.: "The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial". Ann. Intern. Med., 1999, 130, 897.
18. Weiss S.R., Ellman H., Dolker M.: "A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group". Obstet. Gynecol., 1999, 94, 330.
19. Schneider D.L., Barrett-Connor E.L., Morton DJ.: "Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study". JAMA, 1997, 277, 543.
20. Lindsay R., Tohme J.F.: "Estrogen treatment of patients with established postmenopausal osteoporosis". Obstet. Gynecol., 1990, 76, 290.
21. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al.: "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial". JAMA. 2002, 288, 321.
22. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA, 2004, 291 (14), 1701.
23. Bagger Y.Z., Tanko L.B., Alexandersen P., Hansen H.B., Mollgaard A., Ravn P., Qvist P., Kanis J.A., Christiansen C.: "Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study". Bone, 2004, 34 (4), 728.
24. Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric, 2004, 7, 210.
25. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C. et al.: "Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group". J. Clin. Endocrinol. Metab., 2000, 85, 4118.
26. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C. et al.: "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group". N. Engl. J. Med., 2001, 344, 333.
27. McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S. et al.: "Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group". Ann. Intern. Med., 1998, 128, 253.
28. Ravn P., Bidstrup M., Wasnich R.D., Davis J.W., McClung M.R., Balske A. et al.: "Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial". Ann. Intern. Med., 1999, 131, 935.
29. Mortensen L., Charles P., Bekker P.J., Digennaro J., Johnston C.C. Jr.: "Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up". J. Clin. Endocrinol. Metab., 1998, 83, 396.
30. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D. et al.: "Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group". J. Clin. Endocrinol. Metab., 2000, 85, 3109.
31. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L. et al.: "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group". Osteoporos. Int., 2000, 11, 83.
32. Harris ST., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M. et al.: "Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group". JAMA, 1999, 282, 1344.
33. Strewler G.J.: "Decimal point-osteoporosis therapy at the 10-year mark". N. Engl. J. Med., 2004, 350, 1172.
34. rd et al.: "The Alendronate Once-Weekly Study Group. Two year results of once weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis". J. Bone Miner. Res., 2002, 17, 1988.
35. Green J.R., Muller K., Jaeggi K.A.: "Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound". J. Bone Miner. Res., 1994, 9, 745.
36. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U. et al.: "Intravenous zoledronic acid in postmenopausal women with low bone mineral density". N. Engl. J. Med., 2002, 346, 653.
37. Ettinger B., Black D.M., Mitlak B.H. et al.: "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators". JAMA, 1999, 282, 637.
38. Kanis J.A., Johnell O., Black D.M. et al.: "Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial". Bone, 2003, 33, 293.
39. Cauley J.A., Norton L., Lippman M.E. et al.: "Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation". Breast Cancer Res. Treat., 2001, 65, 125.
40. Barrett-Connor E., Grady D., Sashegyi A. et al.: "Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial". JAMA, 2002, 287, 847.
41. Moore R.A.: "Livial: a review of clinical studies". Br. J. Obstet. Gynaecol., 1999, 106 (suppl. 19), 1.
42. Gordana M. et al.: "The effect of Tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis-8 year's follow-up". Maturitas, 2004, 47, 229.
43. Chesnut C. III, Silverman S., Andriano K. et al.: "A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group". Am. J. Med., 2000, 109, 267.
44. Jiang Y., Zhao J.J., Mitlak B.H. et al.: "Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure". J. Bone Miner. Res., 2003, 18, 1932.
45. Zanchetta J.R., Bogado C.E., Ferretti J.L., Wang O., Wilson M.G., Sato M. et al.: "Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis". J. Bone Miner. Res., 2003, 18, 539.
46. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y. et al.: "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis". N. Engl. J. Med., 2001, 344, 1434.
47. Betancourt M., Wirfel K.L., Raymond A.K. et al.: "Osteosarcoma of bone in a patient with primary hyperparathyroidism: A case report". J. Bone Miner. Res., 2003, 18, 163.
48. Sorbera L.A., Leeson P.A.: "ALX1-11 Treatment of osteoporosis (rhPTH1-84) recombinant human parathyroid hormone". Drugs of the Future, 2000, 25, 1007.
49. Reginster J.T., Deroisy R., Dougados M. et al.: "Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double masked, dose ranging, placebo controlled PREVOS trial". Osteoporos. Int., 2002, 13, 925.
50. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D. et al.: "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis". N. Engl. J. Med., 2004, 350, 459.
51. Douglas C.B., Greg R.M.: "Use of statins and fracture results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials". Arch. Intern. Med., 2004, 164, 146.